Sponsored

  • Female
  • 07/07/1996
  • Followed by 4 people
Recent Updates
  • The Artificial Intelligence in Oncology market is anticipated to grow at a CAGR of 54% claims Roots Analysis

    The success of currently employed artificial intelligence (AI) solutions has encouraged researchers to explore the potential of such technologies in the healthcare sector, with its prime focus being oncology, to enable the treatment of several prevalent malignancies.

    London

    Roots Analysis has announced the addition of “Artificial Intelligence in Oncology Market, 2022-2035” report to its list of offerings.

    Several AI technologies demonstrating the potential to diagnose precancerous lesions are expected to be capable of reducing mortality rates by improving detection accuracy, speed and providing assistance in clinical decision-making. This is further expected to result in better clinical outcomes. Overall, this domain is anticipated to gain significant traction, in the foreseen future.

    Key Market Insights

    Over 76 companies claim to be engaged in the development of AI in oncology software solutions
    The AI in diagnostics market is dominated by companies based in North America, primarily in the US; of these, majority were established post 2010 and are small firms. Majority of the companies in this domain offer software solutions to hospitals (52%).

    Nearly 2,770 patents have been filed / granted for AI based software solutions targeting oncology
    Reflecting the increasing research efforts of several industry players engaged in this domain, around 60% of the patents focused on the AI in oncology domain were filed / granted in North America, primarily in the US. It is also worth noting that the maximum patents were filed (69%) by non-academic players.

    Partnership activity in this market has increased at a CAGR of 36% over the past five years
    Technology integration agreements emerged as the most popular type of partnership model adopted by AI in oncology software solution providers, representing over 30% of the total instances. It is worth mentioning that 41% of the partnerships in this domain were inked in 2021.

    USD 5.9+ billion has been invested by both private and public investors, since 2017
    The maximum funding amount was raised through venture capital (66%), grants (11%) and seed funding (8%), during the period 2017-2022.

    Europe is anticipated to capture over 30% of the global market share in 2035
    In terms of cancer, the AI in oncology market for solid malignancies is likely to capture the maximum share (33%), followed by the share captured by breast cancer (30%), and this trend is unlikely to change in the foreseen future as well.

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/ai-in-oncology-market/request-sample.html


    For additional details, please visit https://www.rootsanalysis.com/reports/ai-in-oncology-market.html or email [email protected]

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    [email protected]

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/

    The Artificial Intelligence in Oncology market is anticipated to grow at a CAGR of 54% claims Roots Analysis The success of currently employed artificial intelligence (AI) solutions has encouraged researchers to explore the potential of such technologies in the healthcare sector, with its prime focus being oncology, to enable the treatment of several prevalent malignancies. London Roots Analysis has announced the addition of “Artificial Intelligence in Oncology Market, 2022-2035” report to its list of offerings. Several AI technologies demonstrating the potential to diagnose precancerous lesions are expected to be capable of reducing mortality rates by improving detection accuracy, speed and providing assistance in clinical decision-making. This is further expected to result in better clinical outcomes. Overall, this domain is anticipated to gain significant traction, in the foreseen future. Key Market Insights Over 76 companies claim to be engaged in the development of AI in oncology software solutions The AI in diagnostics market is dominated by companies based in North America, primarily in the US; of these, majority were established post 2010 and are small firms. Majority of the companies in this domain offer software solutions to hospitals (52%). Nearly 2,770 patents have been filed / granted for AI based software solutions targeting oncology Reflecting the increasing research efforts of several industry players engaged in this domain, around 60% of the patents focused on the AI in oncology domain were filed / granted in North America, primarily in the US. It is also worth noting that the maximum patents were filed (69%) by non-academic players. Partnership activity in this market has increased at a CAGR of 36% over the past five years Technology integration agreements emerged as the most popular type of partnership model adopted by AI in oncology software solution providers, representing over 30% of the total instances. It is worth mentioning that 41% of the partnerships in this domain were inked in 2021. USD 5.9+ billion has been invested by both private and public investors, since 2017 The maximum funding amount was raised through venture capital (66%), grants (11%) and seed funding (8%), during the period 2017-2022. Europe is anticipated to capture over 30% of the global market share in 2035 In terms of cancer, the AI in oncology market for solid malignancies is likely to capture the maximum share (33%), followed by the share captured by breast cancer (30%), and this trend is unlikely to change in the foreseen future as well. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/ai-in-oncology-market/request-sample.html For additional details, please visit https://www.rootsanalysis.com/reports/ai-in-oncology-market.html or email [email protected] You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Artificial Intelligence In Oncology Market | Market Size | 2035
    Artificial Intelligence In Oncology / AI in Oncology Market is anticipated to grow at over 50% CAGR driven by nearly USD 6 billion investment in the recent years
    0 Comments 0 Shares
  • The precision medicine software developers market is projected to grow at an annualized rate of 30%
    Given their ability to cater to the existing unmet needs in the healthcare sector, various industry stakeholders have made investments for the development and implementation of precision medicine software applications for diagnosis, analysis and treatment of a range of disorders.   Roots Analysis has announced the addition of “Precision Medicine Software Market 2021-2032”...
    0 Comments 0 Shares
  • Medical Device Developers have been Compelled to Outsource their Manufacturing Operations to Contract Service Providers
    The in-house development of peptide API requires necessary expertise and capabilities, including design, construction and maintenance of a facility which demands significant capital investments. Therefore, several small drug developers and, at times, certain pharma giants as well, have started outsourcing their manufacturing operations to contract service providers.   Over the years, the...
    0 Comments 0 Shares
More Stories
Sponsored


Don't forget, ads time: PentaVerge | AQU | Debwan | ICICTE | Nasseej | ESol | OUST | CorpSNet | PoemsBook | TopDeals | TheReaderView